Moderna, Inc.
A biotechnology company that uses messenger RNA (mRNA) to build medicines and vaccines, best known for Spikevax, its COVID-19 vaccine. Founded in 2010 in Cambridge, Massachusetts, it grew out of the venture-building firm Flagship Pioneering with help from scientists including MIT's Robert Langer. Its name blends "modified" and "RNA"—and conveniently hides the word "modern."
Granted 699.3K
Granted 33.1K · Sold 33.1K
Granted 326.1K · Sold 266.7K
Granted 105.6K · Sold 17.4K
Granted 93.5K
Granted 12.2K
Granted 16.2K
Granted 16.2K
Granted 17.7K · Sold 6.2K
Granted 8.1K
Granted 4.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bancel StephaneChief Executive Officer, Director · 3 transactions | — | 48.36M | 699.3K | — | — |
| Afeyan NoubarDirector · 4 transactions | — | 6.86M | 33.1K | — | 33.1K |
| Hoge StephenPresident · 33 transactions | +1.9% | 1.64M | 326.1K | — | 266.7K |
| Klinger Shannon ThymeChief Legal Officer · 34 transactions | +181% | 79.3K | 105.6K | — | 17.4K |
| Mock James MChief Financial Officer · 30 transactions | +307.7% | 71.4K | 93.5K | — | — |
| Nader FrancoisDirector · 1 transaction | +59.1% | 32.8K | 12.2K | — | — |
| Nabel Elizabeth GDirector · 1 transaction | +526.4% | 19.3K | 16.2K | — | — |
| Horning SandraDirector · 1 transaction | +690.2% | 18.6K | 16.2K | — | — |
| Hussain AbbasDirector · 4 transactions | +1980.3% | 12.1K | 17.7K | — | 6.2K |
| Rubenstein David M.Director · 1 transaction | +531.5% | 9.6K | 8.1K | — | — |
| Tallett Elizabeth EDirector · 1 transaction | +577.2% | 4.8K | 4.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -323.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.